ClinicalTrials.gg
CompletedNCT06642584Updated Oct 20, 2025

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV

A Phase 1 interventional study of Semaglutide B and Semaglutide J in Healthy Volunteers Type 2 Diabetes, sponsored by Novo Nordisk A/S. Completed at 1 site in Canada. Open to male participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-20.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.

Enrollment
97th of 163
90 · median 104
Started
2024
with 17 others
Phase 1
41 of 163
3 open now
Registered
139th of 163
by date
Lead sponsor
89 of 163
Novo Nordisk A/S

Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 97th largest by enrollment, is one of 18 that started in 2024, is one of 41 in phase 1, and was the 139th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 64 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies testing semaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study is conducted to compare four different tablets containing the investigational medicine semaglutide at the same dose. It is done to test how semaglutide in each of the tablet versions is taken up in the body. Which treatments participants will receive is decided by chance. The study will last for about 28 weeks. The study will enroll healthy male participants.

03

Conditions studied

  • Healthy Volunteers Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male.
  2. Age 18-64 years (both inclusive) at the time of signing the .
  3. (BMI) between 22.0 and 31.9 kilogram per square meter (kg/m\^2) (both inclusive) at screening.
  4. Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected to study interventions or related products.
  2. Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
  3. Use of prescription medicinal products or non-prescription drugs, except routine vitamins, topical medication not reaching the systemic circulation and occasional use of paracetamol (acetaminophen) and ibuprofen, within 14 days prior to first dosing.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Sequence 1: Semaglutide J then Semaglutide L

    Participants will receive subcutaneously semagutide B in treatment period 1 followed by oral semaglutide J then semaglutide L in treatment period 2.

    Drug: Semaglutide B · Drug: Semaglutide J · Drug: Semaglutide L

  • Experimental
    Sequence 2: Semaglutide L then Semaglutide J

    Participants will receive subcutaneously semagutide B in treatment period 1 followed by oral semaglutide L then semaglutide J in treatment period 2.

    Drug: Semaglutide B · Drug: Semaglutide J · Drug: Semaglutide L

  • Experimental
    Sequence 3: Semaglutide J then Semaglutide M

    Participants will receive subcutaneously semagutide B in treatment period 1 followed by oral semaglutide J then semaglutide M in treatment period 2.

    Drug: Semaglutide B · Drug: Semaglutide J · Drug: Semaglutide M

  • Experimental
    Sequence 4: Semaglutide M then Semaglutide J

    Participants will receive subcutaneously semagutide B in treatment period 1 followed by oral semaglutide M then semaglutide J in treatment period 2.

    Drug: Semaglutide B · Drug: Semaglutide J · Drug: Semaglutide M

  • Experimental
    Sequence 5: Semaglutide J then Semaglutide N

    Participants will receive subcutaneously semagutide B in treatment period 1 followed by oral semaglutide J then semaglutide N in treatment period 2.

    Drug: Semaglutide B · Drug: Semaglutide J · Drug: Semaglutide N

  • Experimental
    Sequence 6: Semaglutide N then Semaglutide J

    Participants will receive subcutaneously semagutide B in treatment period 1 followed by oral semaglutide N then semaglutide J in treatment period 2.

    Drug: Semaglutide B · Drug: Semaglutide J · Drug: Semaglutide N

Interventions

  • Semaglutide B will be administered subcutaneously.

  • Semaglutide J will be administered as oral tablets.

  • DrugSemaglutide L

    Semaglutide L will be administered as oral tablets.

  • DrugSemaglutide M

    Semaglutide M will be administered as oral tablets.

  • DrugSemaglutide N

    Semaglutide N will be administered as oral tablets.

06

What researchers measure

Primary outcomes

  1. Adjusted AUC(sema); adjusted area under the semaglutide plasma concentration-time curve

    Measured in hours nanomoles per liter (h \* nmol/L).

    Time frame: From 0 to 24 hours after dosing on Days 122 and 132.

  2. Adjusted Cmax,(sema); adjusted maximum observed semaglutide plasma concentration

    Measured in nanomoles per liter(nmol/L).

    Time frame: From 0 to 24 hours after dosing on Days 122 and 132.

  3. Adjusted tmax,sema; time to adjusted maximum observed semaglutide plasma concentration

    Measured in hours.

    Time frame: From 0 to 24 hours after dosing on Days 122 and 132.

  4. t½,sema; the terminal half-life of semaglutide

    Measured in hours.

    Time frame: From 0 to 840 hours after dosing on Day 132.

07

Study locations

1 site
  • Altasciences
    Montreal, Quebec H3P 3P1, Canada
08

References and documents

Individual participant data

Plan to share: Yes — "According to the Novo Nordisk disclosure commitment on novonordisk-trials.com"

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Jul 2025, 8 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 8 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2024
First posted
Oct 15, 2024
StartActual
Oct 15, 2024
Primary completionActual
Jul 10, 2025
CompletionActual
Aug 13, 2025
Last update
Oct 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06642584
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Oct 15, 2024
Primary completion
Jul 10, 2025
Completion
Aug 13, 2025
Last update
Oct 20, 2025

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion